Skip to main
MEDP

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Medpace Holdings is well-positioned for future growth due to strong pre-backlog growth, a diversified portfolio, and normalized cancellations. Furthermore, the company's shift toward oncology and tighter backlog recognition policy provide a structural buffer against potential future cancellation spikes. With a highly efficient headcount and an overall positive outlook for the biopharma industry, Medpace is in a strong position to continue its growth trajectory in the coming years.

Bears say

Medpace Holdings is a full-service contract research organization (CRO) focused on providing outsourced clinical development services to the biotech, pharmaceutical, and medical device industries. With a heavy reliance on the biotech industry, any slowdown in funding for these customers could severely impact Medpace's bookings and revenue growth. Additionally, any delays or cancellations of clinical trials could negatively impact the company's reputation and long-term performance, and there is also a risk of data breaches or a shortage of trained talent leading to slower clinical trial start times.

Medpace Holdings (MEDP) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 10 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $560.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $560.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.